Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities
Authors
Keywords
HGF/c-Met, PI3K/AKT, Ras/MAPK, Wnt, RON, EGFR, Therapeutic strategy
Journal
Molecular Cancer
Volume 17, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-02-15
DOI
10.1186/s12943-018-0796-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma
- (2017) Ignace B. Vergote et al. EUROPEAN JOURNAL OF CANCER
- Tivantinib for the treatment of hepatocellular carcinoma
- (2017) Jan Best et al. EXPERT OPINION ON PHARMACOTHERAPY
- C-Met as a potential target for the treatment of gastrointestinal cancer: Current status and future perspectives
- (2017) Afsane Bahrami et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Intracranial Activity of Cabozantinib in MET Exon 14–Positive NSCLC with Brain Metastases
- (2017) Samuel J. Klempner et al. Journal of Thoracic Oncology
- Role of long non-coding RNAs in glucose metabolism in cancer
- (2017) Chunmei Fan et al. Molecular Cancer
- Circular RNAs in human cancer
- (2017) Yumin Wang et al. Molecular Cancer
- Dual Inhibition of Hedgehog and c-Met Pathways for Pancreatic Cancer Treatment
- (2017) Agnieszka A. Rucki et al. MOLECULAR CANCER THERAPEUTICS
- MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale
- (2017) Ravi Salgia MOLECULAR CANCER THERAPEUTICS
- Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma
- (2017) Hanyin Cheng et al. MOLECULAR CANCER THERAPEUTICS
- RON and c-Met facilitate metastasis through the ERK signaling pathway in prostate cancer cells
- (2017) Binbin Yin et al. ONCOLOGY REPORTS
- The c-Met receptor: Implication for targeted therapies in colorectal cancer
- (2017) Elmira Safaie Qamsari et al. TUMOR BIOLOGY
- The Involvement of Hepatocyte Growth Factor-MET-Matrix Metalloproteinase 1 Signaling in Bladder Cancer Invasiveness and Proliferation. Effect of the MET Inhibitor, Cabozantinib (XL184), on Bladder Cancer Cells
- (2017) Terumichi Shintani et al. UROLOGY
- Anti-c-Met antibody bioconjugated with hollow gold nanospheres as a novel nanomaterial for targeted radiation ablation of human cervical cancer cell
- (2017) Ying Liang et al. Oncology Letters
- MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor
- (2017) Sean Caenepeel et al. Oncotarget
- Role of tumor microenvironment in tumorigenesis
- (2017) Maonan Wang et al. Journal of Cancer
- Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines
- (2017) Aryan Stanley et al. Scientific Reports
- Functional and therapeutic relevance of hepatocyte growth factor/c-MET signaling in synovial sarcoma
- (2016) Yoshinori Imura et al. CANCER SCIENCE
- Hepatic stellate cell promoted hepatoma cell invasion via the HGF/c-Met signaling pathway regulated by p53
- (2016) Wen-Ting Liu et al. CELL CYCLE
- c-Met inhibition enhances chemosensitivity of human ovarian cancer cells
- (2016) Jing Wang et al. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
- Cabozantinib for the treatment of renal cell carcinoma
- (2016) Bernard Escudier et al. EXPERT OPINION ON PHARMACOTHERAPY
- Interaction between Wnt/β-catenin pathway and microRNAs regulates epithelial-mesenchymal transition in gastric cancer (Review)
- (2016) CUNEN WU et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Acid sphingomyelinase is required for cell surface presentation of Met receptor tyrosine kinase in cancer cells
- (2016) Linyu Zhu et al. JOURNAL OF CELL SCIENCE
- Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
- (2016) Toni K Choueiri et al. LANCET ONCOLOGY
- In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models
- (2016) Paul E. Hughes et al. MOLECULAR CANCER THERAPEUTICS
- Targeting c-MET by LY2801653 for treatment of cholangiocarcinoma
- (2016) Samarpita Barat et al. MOLECULAR CARCINOGENESIS
- Recurrent MET fusion genes represent a drug target in pediatric glioblastoma
- (2016) NATURE MEDICINE
- Blood vessel endothelium-directed tumor cell streaming in breast tumors requires the HGF/C-Met signaling pathway
- (2016) E Leung et al. ONCOGENE
- Apigenin Inhibits Cancer Stem Cell-Like Phenotypes in Human Glioblastoma Cells via Suppression of c-Met Signaling
- (2016) Boram Kim et al. PHYTOTHERAPY RESEARCH
- Heteronemin Is a Novel c-Met/STAT3 Inhibitor Against Advanced Prostate Cancer Cells
- (2016) Jian-Ching Wu et al. PROSTATE
- Beta 1-integrin–c-Met cooperation reveals an inside-in survival signalling on autophagy-related endomembranes
- (2016) Rachel Barrow-McGee et al. Nature Communications
- A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)
- (2015) H. Yoshioka et al. ANNALS OF ONCOLOGY
- Effects of Exercise on Tumor Physiology and Metabolism
- (2015) Line Pedersen et al. CANCER JOURNAL
- Phase I study of tivantinib in Japanese patients with advanced hepatocellular carcinoma: Distinctive pharmacokinetic profiles from other solid tumors
- (2015) Takuji Okusaka et al. CANCER SCIENCE
- Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Giorgio Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
- Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma
- (2015) Qingfeng Xiang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches
- (2015) Meghan Shea et al. Therapeutic Advances in Respiratory Disease
- HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer
- (2015) Marisa Mariani et al. Oncotarget
- Ron Receptor Tyrosine Kinase Activation Confers Resistance to Tamoxifen in Breast Cancer Cell Lines
- (2015) Rebecca J. McClaine et al. NEOPLASIA
- Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors
- (2014) Igor Puzanov et al. INVESTIGATIONAL NEW DRUGS
- EGFR and c-Met Cross Talk in Glioblastoma and Its Regulation by Human Cord Blood Stem Cells
- (2014) Kiran Kumar Velpula et al. Translational Oncology
- EGF Receptor Activates MET through MAPK to Enhance Non-Small Cell Lung Carcinoma Invasion and Brain Metastasis
- (2013) J. L. Breindel et al. CANCER RESEARCH
- Targeting the MET gene for the treatment of non-small-cell lung cancer
- (2013) F. Gelsomino et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- The Wnt/β-catenin pathway in ovarian cancer: A review
- (2013) Rebecca C. Arend et al. GYNECOLOGIC ONCOLOGY
- Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer
- (2013) Manish A. Shah et al. PLoS One
- Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent
- (2013) M. Merchant et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- In Vitro and In Vivo Activity of Cabozantinib (XL184), an Inhibitor of RET, MET, and VEGFR2, in a Model of Medullary Thyroid Cancer
- (2013) Frauke Bentzien et al. THYROID
- Combined Wnt/β-Catenin, Met, and CXCL12/CXCR4 Signals Characterize Basal Breast Cancer and Predict Disease Outcome
- (2013) Jane D. Holland et al. Cell Reports
- Knockdown of RON receptor kinase delays but does not prevent tumor progression while enhancing HGF/MET signaling in pancreatic cancer cell lines
- (2013) S Zhao et al. Oncogenesis
- Met Kinase Inhibitor E7050 Reverses Three Different Mechanisms of Hepatocyte Growth Factor-Induced Tyrosine Kinase Inhibitor Resistance in EGFR Mutant Lung Cancer
- (2012) W. Wang et al. CLINICAL CANCER RESEARCH
- Targeting the HGF/Met signaling pathway in cancer therapy
- (2012) Fabiola Cecchi et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma
- (2012) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Wnt/β-catenin signaling is a key downstream mediator of MET signaling in glioblastoma stem cells
- (2012) Kang Ho Kim et al. NEURO-ONCOLOGY
- Lung cancer: New biological insights and recent therapeutic advances
- (2011) Suresh S. Ramalingam et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Ron Kinase Transphosphorylation Sustains MET Oncogene Addiction
- (2011) S. Benvenuti et al. CANCER RESEARCH
- A Novel Kinase Inhibitor, INCB28060, Blocks c-MET-Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3
- (2011) X. Liu et al. CLINICAL CANCER RESEARCH
- c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma
- (2011) Hanning You et al. HEPATOLOGY
- Distinct Involvement of the Gab1 and Grb2 Adaptor Proteins in Signal Transduction by the Related Receptor Tyrosine Kinases RON and MET
- (2011) Amitabha Chaudhuri et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung Cancer
- (2011) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Breast Cancer-Derived Bone Metastasis Can Be Effectively Reduced through Specific c-MET Inhibitor Tivantinib (ARQ 197) and shRNA c-MET Knockdown
- (2011) S. Previdi et al. MOLECULAR CANCER THERAPEUTICS
- Met Activation in Non-Small Cell Lung Cancer Is Associated with de Novo Resistance to EGFR Inhibitors and the Development of Brain Metastasis
- (2010) Elisa Benedettini et al. AMERICAN JOURNAL OF PATHOLOGY
- Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
- (2010) Alexa B. Turke et al. CANCER CELL
- Silencing of RON Receptor Signaling Promotes Apoptosis and Gemcitabine Sensitivity in Pancreatic Cancers
- (2010) J. Logan-Collins et al. CANCER RESEARCH
- Acquired Resistance of Non-Small Cell Lung Cancer Cells to MET Kinase Inhibition Is Mediated by a Switch to Epidermal Growth Factor Receptor Dependency
- (2010) U. McDermott et al. CANCER RESEARCH
- Targeting the HGF/Met signalling pathway in cancer
- (2010) Fabiola Cecchi et al. EUROPEAN JOURNAL OF CANCER
- Interaction between human-breast cancer metastasis and bone microenvironment through activated hepatocyte growth factor/Met and β-catenin/Wnt pathways
- (2010) Sara Previdi et al. EUROPEAN JOURNAL OF CANCER
- Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells
- (2009) S Agarwal et al. BRITISH JOURNAL OF CANCER
- Cyclooxygenase-2 Inhibition Inhibits c-Met Kinase Activity and Wnt Activity in Colon Cancer
- (2008) J. B. Tuynman et al. CANCER RESEARCH
- Met and c-Src Cooperate to Compensate for Loss of Epidermal Growth Factor Receptor Kinase Activity in Breast Cancer Cells
- (2008) K. L. Mueller et al. CANCER RESEARCH
- AKT Signaling in Regulating Angiogenesis
- (2008) Bing-Hua Jiang et al. CURRENT CANCER DRUG TARGETS
- Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma
- (2008) Ai-Wu Ke et al. HEPATOLOGY
- Smad4-dependent TGF-β Signaling Suppresses RON Receptor Tyrosine Kinase-dependent Motility and Invasion of Pancreatic Cancer Cells
- (2008) Shujie Zhao et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutations
- (2008) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Re: Prognostic Value of MET, RON and Histoprognostic Factors for Urothelial Carcinoma in the Upper Urinary Tract
- (2008) Jay D. Raman JOURNAL OF UROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started